Ash Stevens, Inc. has received FDA approval for its facility in Riverview, MI for the manufacture of Amotosalen, the API in Cerus Corp.’s (CERS) INTERCEPT Blood System. The INTERCEPT Blood System recently received FDA approval for ex vivo preparation of pathogen-reduced plasma and platelet components in order to reduce the risk of transfusion-transmitted infection (TTI).   “We are proud to be Cerus Corp.’s outsourcing partner for the development and manufacture of this importan...